= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Adhikari

MSACL 2018 EU Abstract

Topic: Metabolomics

Podium Presentation in the Ether on Thursday at 11:20 (Chair: Nicola Gray)

Clinical Validation of an Automated Dried Blood Spot Sampling Device – Fluispotter®

Khem Adhikari (Presenter)
Rigshospitalet

Presenter Bio(s): I am in the third year of my postdoc research career and in the second year of my current position. I did my PhD in Analytical Chemistry from Denmark (2014) and MSc in Nutritional Sciences (2009) from Israel.

Currently, I am working on an analytical method development and validation for cortisol in dried blood spot (DBS) as a part of the project for clinical validation of an automatic, wearable, 20-hours DBS sampling device.

I apply the-state-of-art mass spectrometry instruments in various uses of clinical, food/nutrition, agriculture, clinical and environmental aspects.

Since 2011 method development, validation, quality control, quantitative analysis and metabolite identification in various matrices has been my main focus. It primarily covers various sample preparation processes, LC-MS/MS method development and validation, sample and data analyses.

Authors: Khem Bahadur Adhikari1*, Ruth Frikke-Schmidt (1), Ulla Feldt-Rasmussen (2), Jesper Johannesen (3), Sten Velschow (4), Malene Schrøder (4), Anders Holten Johnsen (1)
(1) Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark (2) Department of Endocrinology, Rigshospitalet, Copenhagen, Denmark (3) Department of Paediatrics, Herlev Hospital, Copenhagen, Denmark (4) Fluisense ApS, Lillerød, Denmark

Abstract

The use of dried blood spot (DBS) samples for the quantitative analysis has received increasing attention in the recent years. An accurate micro-volume spotting, 20-hours, automated and wearable DBS sampler, “Fluispotter®”, has been used and the analytical method for cortisol has been thoroughly validated as proof of concept. The method has good precision and accuracy and the device is well suited for clinical trials.


Financial Disclosure

DescriptionY/NSource
Grantsno
SalaryyesRigshospitalet
Board Memberno
Stockno
Expensesno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above:

yes